• Users Online: 89
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2020  |  Volume : 14  |  Issue : 2  |  Page : 130-135

Effect of De novo donor-specific antibodies on graft function in renal allograft recipients


1 Institute of Renal Sciences, Sir Ganga Ram Hospital, New Delhi, India
2 HLA and Immunogenetics Laboratory, Sir Ganga Ram Hospital, New Delhi, India

Correspondence Address:
Dr. Ravi Kumar Singh
Institute of Renal Sciences, Sir Ganga Ram Hospital, New Delhi
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijot.ijot_6_20

Get Permissions

Background: De novo formation of donor-specific antibodies (DSA) against donor human leukocyte antigens (HLAs) class I and II has been recognized as one of the major risk factors for reduced allograft survival. This study aimed to detect the de novo DSA in renal transplanted recipients and their association with graft function. Methods: This was a retro-prospective observational study conducted from July 2017 to March 2019. The patients with pretransplant DSA-negative renal allograft and those who fulfilled the inclusion criteria were enrolled. Posttransplant, HLA-specific antibodies were tested using a panel reactive antibody (PRA) screen and a positive PRA screen was further tested by Luminex crossmatch assay. Posttransplant biochemical data were assessed for 6-, 12-, and 18-month follow-ups. Results: A total of 72 patients were included in this study, of which 63 were diagnosed as de novo DSA negative, and nine were diagnosed as de novo DSA positive. At 18-month follow-up, in the patients with de novo DSA positive, 55.55% patients showed positive DSA levels for HLA Class II, 33.33% patients showed border-line DSA levels for HLA Class II, and 11.11% patients showed border-line DSA levels for HLA Class I (P < 0.001). Proteinuria was high in de novo DSA-positive patients than de novo DSA negative while serum creatinine, estimated glomerular filtration rate, and tacrolimus level were comparable between groups at 6-, 12-, 18-month follow-up periods. Conclusion: The incidence of de novo DSA was developed in 12.5% of patients; however, there was no significant graft dysfunction.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed83    
    Printed5    
    Emailed0    
    PDF Downloaded17    
    Comments [Add]    

Recommend this journal